InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
4
T+90 hit rate
75%
T+90 mean return
+14.5%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by TANNENBAUM RENEE P, Administratrice. Director active across 3 companies, notably Zogenix, INC.. In total, 14 reports have been recorded. Split: 4 buys · 4 sells. Total volume traded: €536k. Activity tracked since 1 June 2021. The latest transaction was filed on 21 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations14 total
4,357 shares0Common StockSEC:0001543174-26-000003:0
1,800 shares@ US$81.1551.6% of flowCommon StockSEC:0001543174-25-000006:0
4,336 shares0Common StockSEC:0001543174-25-000002:0
10,000 shares@ US$3.422474.8% of flowCommon StockSEC:0000950170-24-136725:0
Ideal exit: 8 Sept 2025 (T+270)
4,410 shares0Common StockSEC:0001543174-24-000005:0
2,000 shares@ US$63.8748.4% of flowCommon StockSEC:0001543174-24-000002:0
6,865 shares0Common StockSEC:0001104659-23-064160:0
6,400 shares@ US$1.71525.2% of flowCommon StockSEC:0001628280-22-025101:0
Ideal exit: 12 Jun 2023 (T+270)
13,346 shares0Common StockSEC:0001415889-22-003266:0
32,567 sharesCommon StockSEC:0000899243-22-010303:0
5,305 shares@ US$11.7222.1% of flowCommon StockSEC:0001375151-21-000102:0
5,305 shares@ US$11.7222.1% of flowCommon StockSEC:0001375151-21-000102
5,000 shares@ US$17.049527.9% of flowCommon StockSEC:0001375151-21-000072:0
Ideal exit: 26 Feb 2022 (T+270)
5,000 shares@ US$17.049527.9% of flowCommon StockSEC:0001375151-21-000072
Ideal exit: 26 Feb 2022 (T+270)
14 of 14 declarations
About TANNENBAUM RENEE P
Renee P. Tannenbaum is a Board Member at Zogenix, Inc. and ANI Pharmaceuticals Inc. She participates in the governance and strategy of these companies. With significant experience in the pharmaceutical sector, Renee brings valuable expertise in product development and regulation. Her commitment to innovation and improving healthcare is an asset for Zogenix and ANI.
